Hemostemix Inc. Share Price

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. 14:30:00 15/09/2026 BST			5-day change	1st Jan Change
0.0700 ^CAD	-6.67%		-6.67%	-22.22%

09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI

News in other languages: Hemostemix Inc.

10/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
22/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
09/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors: Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	09/02/2020
Christina Wu DFI	Director of Finance/CFO	-	04/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	13/10/2021

Director	Title	Age	Since
Peter Lacey CHM	Chairman	69	10/03/2020
Ronnie Hershmann BRD	Director/Board Member	67	08/02/2020
Thomas Smeenk BRD	Director/Board Member	-	25/11/2019

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
15/09/26	CA$0.0700	-6.67%	2,023
14/09/26	CA$0.0750	+7.14%	21,796
11/09/26	CA$0.0700	-6.67%	37,900
10/09/26	CA$0.0750	0.00%	15,911
09/09/26	CA$0.0750	0.00%	2,000

Delayed Quote Toronto S.E.

More quotes

Market Cap	14.8M 10.63M 9.21M 8.71M 7.89M 1.02B 14.91M 104M 39.99M 517M 39.95M 39.06M 1.65B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	17.66M 12.69M 10.99M 10.39M 9.41M 1.22B 17.79M 124M 47.72M 617M 47.67M 46.61M 1.97B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	83.37%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Toronto S.E.	HEM	Delayed
Tradegate	2VF0	Real-time
OTC Markets	HMTXF	Delayed
Deutsche Boerse AG	2VF0	Delayed
Börse Stuttgart	2VF0	Delayed

09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI
07-31	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-16	Hemostemix Inc. amended terms of the transaction	CI
05-29	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-25	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-20	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
05-01	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-18	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT

08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA	NE
08-12	Hemostemix : Dr. Ernst von Schwarz named PI of Hemostemix Longevity Clinical Trial	PU
08-12	Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial	NE
07-28	Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results	NE
07-22	Hemostemix : grants 6,280,000 options	PU

1 day	-6.67%
1 week	-6.67%
Current month	-6.67%
1 month	+7.69%
3 months	+27.27%
6 months	-12.50%
Current year	-22.22%

Hemostemix Inc. Share Price

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation: Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news: Hemostemix Inc.

Press Releases: Hemostemix Inc.

News in other languages: Hemostemix Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	0.07	0.08
1 month	0.07	0.08
Current year	0.04	0.11
1 year	0.04	0.12
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/07/26	Peter Lacey	Option	Chairman	525,000	0.2654%
22/07/26	Loran Swanberg	Option	Director	385,000	0.1946%
22/07/26	Thomas Smeenk	Option	Founder	1,730,000	0.8746%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	-6.67%	-6.67%	-30.00%	-44.00%	10.63M
WUXI APPTEC CO., LTD.	-1.38%	+0.20%	+46.42%	+96.33%	69.18B
ARGENX SE	-0.37%	-1.11%	+35.68%	+75.26%	62B
INSMED INCORPORATED	-4.29%	-3.98%	-16.22%	+350.66%	26.19B
WUXI BIOLOGICS (CAYMAN) INC.	+1.46%	+2.25%	+28.84%	+14.54%	25.75B
BIONTECH SE	-2.20%	-2.00%	-1.22%	-14.48%	24.29B
GENMAB A/S	+4.07%	+4.87%	+26.12%	-14.02%	19.84B
PHARMAESSENTIA CORPORATION	+1.26%	-14.23%	+170.04%	+298.75%	15.65B
SUMMIT THERAPEUTICS INC.	-5.54%	+0.69%	-8.13%	+830.48%	13.88B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.39%	-4.24%	-9.86%	+454.94%	14.09B
Average	-1.41%	-1.98%	+24.17%	+204.85%	27.09B
Weighted average by Cap.	-0.85%	-1.32%	+31.90%	+158.26%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.88M -1.63M -1.54M -1.39M -180M -2.64M -18.38M -7.07M -91.44M -7.06M -6.91M -292M	-4.71M -3.39M -2.93M -2.77M -2.51M -325M -4.75M -33.11M -12.74M -165M -12.72M -12.44M -525M
Net Debt	4.23M 3.04M 2.63M 2.49M 2.25M 292M 4.26M 29.72M 11.43M 148M 11.42M 11.17M 472M	2.86M 2.06M 1.78M 1.68M 1.52M 197M 2.88M 20.09M 7.73M 99.98M 7.72M 7.55M 319M